Photo of Lawrence N. Shulman,  MD

Lawrence N. Shulman, MD

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute
Phone: (617) 632-2277
Fax: (617) 632-2260

Lawrence N. Shulman, MD

Dana-Farber Cancer Institute

EDUCATIONAL TITLES

  • Associate Professor, Medicine, Harvard Medical School
  • Physician, Adult Oncology, Brigham And Women's Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

My research is focused on the delivery of cancer care in resource-constrained settings, particularly Rwanda and Haiti. Implementation science, cancer epidemiology and outcomes research are included in the portfolio. Plans are underway to initiate research in basic tumor biology from patients in these areas. In addition, research and efforts in global cancer policy are an important component of these activities.

Publications

Powered by Harvard Catalyst
  • Son BH, Dominici LS, Aydogan F, Shulman LN, Ahn SH, Cho JY, Coopey SB, Kim SB, Min HE, Valero M, Wang J, Caragacianu D, Gong GY, Hevelone ND, Baek S, Golshan M. Young women with breast cancer in the United States and South Korea: comparison of demographics, pathology and management. Asian Pac. J. Cancer Prev. 2015; 16:2531-5. PubMed
  • Shulman LN. The effect of accountable care organizations on oncology practice. Am Soc Clin Oncol Educ Book 2014; 34:e468-71. PubMed
  • Shulman LN, Mamon H, Jacobson JO, Steingisser L, Dodek A, Fallon JA. Partnership between a cancer center and payer: opportunities for improved quality of care and cost reduction. J Oncol Pract 2013; 9:133-4. PubMed
  • Keating NL, Landrum MB, Lamont EB, Bozeman SR, Shulman LN, McNeil BJ. Tumor boards and the quality of cancer care. Journal of the National Cancer Institute 2013; 105:113-21. PubMed
  • Wheeler HE, Gamazon ER, Wing C, Njiaju UO, Njoku C, Baldwin RM, Owzar K, Jiang C, Watson D, Shterev I, Kubo M, Zembutsu H, Winer EP, Hudis CA, Shulman LN, Nakamura Y, Ratain MJ, Kroetz DL, , Cox NJ, Dolan ME. Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy. Clin Cancer Res 2013; 19:491-9. PubMed
  • Sharma K, Costas A, Damuse R, Hamiltong-Pierre J, Pyda J, Ong CT, Shulman LN, Meara JG. The Haiti Breast Cancer Initiative: Initial Findings and Analysis of Barriers-to-Care Delaying Patient Presentation. J Oncol 2013; 2013:206367. PubMed
  • Silva TB, Mauad EC, Carvalho AL, Jacobs LA, Shulman LN. Difficulties in implementing an organized screening program for breast cancer in Brazil with emphasis on diagnostic methods. Rural Remote Health 2013; 13:2321. PubMed
  • Weingart SN, Cleary A, Scullion B, Morway L, Phantumvanit V, Stuver SO, Shulman LN, Connors JM. Comparing clinicians' use of an anticoagulation management service and usual care in ambulatory oncology. J Oncol Pharm Pract 2012. PubMed
  • Shulman LN, Cirrincione CT, Berry DA, Becker HP, Perez EA, O'Regan R, Martino S, Atkins JN, Mayer E, Schneider CJ, Kimmick G, Norton L, Muss H, Winer EP, Hudis C. Six cycles of Doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: cancer and leukemia group B 40101. J Clin Oncol 2012; 30:4071-6. PubMed
  • Weingart SN, Mattsson T, Zhu J, Shulman LN, Hassett M. Improving electronic oral chemotherapy prescription: can we build a safer system? J Oncol Pract 2013; 8:e168-73. PubMed
  • Baldwin RM, Owzar K, Zembutsu H, Chhibber A, Kubo M, Jiang C, Watson D, Eclov RJ, Mefford J, McLeod HL, Friedman PN, Hudis CA, Winer EP, Jorgenson EM, Witte JS, Shulman LN, Nakamura Y, Ratain MJ, Kroetz DL. A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin Cancer Res 2012; 18:5099-109. PubMed
  • Solin LJ, Gray R, Goldstein LJ, Recht A, Baehner FL, Shak S, Badve S, Perez EA, Shulman LN, Martino S, Davidson NE, Sledge GW, Sparano JA. Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study. Breast Cancer Res Treat 2012; 134:683-92. PubMed
  • Knaul FM, Shulman LN, Gralow J, Quick J, Bhadelia A, Frenk J. Improving pathology for better cancer care and control in countries of low and middle income. Lancet 2012; 379:2052. PubMed
  • Sharma K, Costas A, Shulman LN, Meara JG. A systematic review of barriers to breast cancer care in developing countries resulting in delayed patient presentation. J Oncol 2012; 2012:121873. PubMed
  • Bunnell CA, Shulman LN. Will we be able to care for cancer patients in the future? Oncology (Huntingt) 2011; 24:1343-8. PubMed
  • Bunnell CA, Weingart SN, Swanson S, Mamon HJ, Shulman LN. Models of multidisciplinary cancer care: physician and patient perceptions in a comprehensive cancer center. J Oncol Pract 2011; 6:283-8. PubMed
  • Farmer P, Frenk J, Knaul FM, Shulman LN, Alleyne G, Armstrong L, Atun R, Blayney D, Chen L, Feachem R, Gospodarowicz M, Gralow J, Gupta S, Langer A, Lob-Levyt J, Neal C, Mbewu A, Mired D, Piot P, Reddy KS, Sachs JD, Sarhan M, Seffrin JR. Expansion of cancer care and control in countries of low and middle income: a call to action. Lancet 2010; 376:1186-93. PubMed
  • Drews RE, Shulman LN. Update in hematology and oncology. Ann Intern Med 2010; 152:655-62. PubMed
  • Weingart SN, Toro J, Spencer J, Duncombe D, Gross A, Bartel S, Miransky J, Partridge A, Shulman LN, Connor M. Medication errors involving oral chemotherapy. Cancer 2010; 116:2455-64. PubMed
  • Shulman LN, Willett W, Sievers A, Knaul FM. Breast cancer in developing countries: opportunities for improved survival. J Oncol 2011; 2010:595167. PubMed
  • Carlson JW, Lyon E, Walton D, Foo WC, Sievers AC, Shulman LN, Farmer P, Nosé V, Milner DA. Partners in pathology: a collaborative model to bring pathology to resource poor settings. Am J Surg Pathol 2009; 34:118-23. PubMed
  • Sparano JA, Goldstein LJ, Childs BH, Shak S, Brassard D, Badve S, Baehner FL, Bugarini R, Rowley S, Perez E, Shulman LN, Martino S, Davidson NE, Sledge GW, Gray R. Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer. Clin Cancer Res 2009; 15:7693-7700. PubMed
  • Weingart SN,Saadeh MG,Simchowitz B,Gandhi TK,Nekhlyudov L,Studdert DM,Puopolo AL,Shulman LN. Process of care failures in breast cancer diagnosis. J Gen Intern Med 2009; 24:702-9. PubMed
  • Burstein HJ,Chen YH,Parker LM,Savoie J,Younger J,Kuter I,Ryan PD,Garber JE,Chen H,Campos SM,Shulman LN,Harris LN,Gelman R,Winer EP. VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res 2008; 14:7871-7. PubMed
  • Ettinger DS,Agulnik M,Cristea M,Eaton K,Fidias PM,Gockerman JP,Hameed O,Handorf C,Harris EI,Jacobs CD,Javle M,Khushalani NI,Kvols L,Lenzi R,Lewis NL,Rashid A,Saltz L,Shulman LN,Zager JS,Zhen W. Occult primary. J Natl Compr Canc Netw 2009; 6:1026-60. PubMed
  • Goldstein LJ,Gray R,Badve S,Childs BH,Yoshizawa C,Rowley S,Shak S,Baehner FL,Ravdin PM,Davidson NE,Sledge GW Jr,Perez EA,Shulman LN,Martino S,Sparano JA. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol 2008; 26:4063-71. PubMed
  • Goldstein LJ,O'Neill A,Sparano JA,Perez EA,Shulman LN,Martino S,Davidson NE. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. J Clin Oncol 2008; 26:4092-9. PubMed
  • Bansal A,Binkert CA,Robinson MK,Shulman LN,Pellerin L,Davison B. Impact of quality management monitoring and intervention on central venous catheter dysfunction in the outpatient chemotherapy infusion setting. J Vasc Interv Radiol 2008; 19:1171-5. PubMed
  • Shulman LN, Hitt RA, Ferry JA. Case records of the Massachusetts General Hospital. Case 4-2008. A 33-year-old pregnant woman with swelling of the left breast and shortness of breath. N Engl J Med 2008; 358:513-23. PubMed
  • Weingart SN, Cleary A, Seger A, Eng TK, Saadeh M, Gross A, Shulman LN. Medication reconciliation in ambulatory oncology. Jt Comm J Qual Patient Saf 2008; 33:750-7. PubMed
  • Cruz GD, Shulman LC, Kumar JV, Salazar CR. The cultural and social context of oral and pharyngeal cancer risk and control among Hispanics in New York. J Health Care Poor Underserved 2007; 18:833-46. PubMed
  • Tolaney SM, Colson YL, Gill RR, Schulte S, Duggan MM, Shulman LN, Winer EP. Sarcoidosis mimicking metastatic breast cancer. Clin Breast Cancer 2007; 7:804-10. PubMed
  • Lin NU, Parker LM, Come SE, Burstein HJ, Haldoupis M, Ryabin N, Gelman R, Winer EP, Shulman LN. Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions. Invest New Drugs 2007; 25:369-75. PubMed
  • Shulman L, Ost D. Advances in bronchoscopic diagnosis of lung cancer. Curr Opin Pulm Med 2007; 13:271-7. PubMed
  • Weingart SN, Flug J, Brouillard D, Morway L, Partridge A, Bartel S, Shulman LN, Connor M. Oral chemotherapy safety practices at US cancer centres: questionnaire survey. BMJ 2007; 334:407. PubMed
  • Bellon JR, Come SE, Gelman RS, Henderson IC, Shulman LN, Silver BJ, Harris JR, Recht A. Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: updated results of a prospective randomized trial. J Clin Oncol 2005; 23:1934-40. PubMed
  • McCollum AD, Kulke MH, Ryan DP, Clark JW, Shulman LN, Mayer RJ, Bartel S, Fuchs CS. Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors. Am J Clin Oncol 2004; 27:485-8. PubMed
  • Canellos GP, Gollub J, Neuberg D, Mauch P, Shulman LN. Primary systemic treatment of advanced Hodgkin's disease with EVA (etoposide, vinblastine, doxorubicin): 10-year follow-up. Ann Oncol 2003; 14:268-72. PubMed
  • Eder JP, Supko JG, Clark JW, Puchalski TA, Garcia-Carbonero R, Ryan DP, Shulman LN, Proper J, Kirvan M, Rattner B, Connors S, Keogan MT, Janicek MJ, Fogler WE, Schnipper L, Kinchla N, Sidor C, Phillips E, Folkman J, Kufe DW. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol 2002; 20:3772-84. PubMed
  • Vasey PA, Shulman LN, Campos S, Davis J, Gore M, Johnston S, Kirn DH, O'Neill V, Siddiqui N, Seiden MV, Kaye SB. Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol 2002; 20:1562-9. PubMed
  • Bunnell CA, Supko JG, Eder JP, Clark JW, Lynch TJ, Kufe DW, Shulman LN. Phase I clinical trial of 7-cyanoquinocarcinol (DX-52-1) in adult patients with refractory solid malignancies. Cancer Chemother Pharmacol 2002; 48:347-55. PubMed
  • Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, Manola J, Younger J, Matulonis U, Bunnell CA, Partridge AH, Richardson PG, Clarke K, Shulman LN, Winer EP. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001; 19:2722-30. PubMed
  • Jacobson JO, Grossbard M, Shulman LN, Neuberg D. CHOP chemotherapy with preemptive granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma: a dose-intensity analysis. Clin Lymphoma 2001; 1:211-7; discussion 218. PubMed
  • Sternberg DW, Aird W, Neuberg D, Thompson L, MacNeill K, Amrein P, Shulman LN. Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine: a pharmacologically based regimen. Cancer 2000; 88:2037-41. PubMed
  • Burstein HJ, Manola J, Younger J, Parker LM, Bunnell CA, Scheib R, Matulonis UA, Garber JE, Clarke KD, Shulman LN, Winer EP. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000; 18:1212-9. PubMed
  • Dubey A, Recht A, Come SE, Gelman RS, Silver B, Harris JR, Shulman LN. Concurrent CMF and radiation therapy for early stage breast cancer: results of a pilot study. Int J Radiat Oncol Biol Phys 1999; 45:877-84. PubMed
  • Shulman LN, Buswell L, Riese N, Doherty N, Loeffler JS, von Roemeling RW, Coleman CN. Phase I trial of the hypoxic cell cytotoxin tirapazamine with concurrent radiation therapy in the treatment of refractory solid tumors. Int J Radiat Oncol Biol Phys 2000; 44:349-53. PubMed
  • Shulman LN, Tarbell NJ, Storen E, Marcus K, Mauch PM. Low-dose total body irradiation and G-CSF without hematopoietic stem cell support in the treatment of relapsed or refractory acute myelogenous leukemia (AML), or AML in second or subsequent remission. Int J Radiat Oncol Biol Phys 1998; 42:1113-7. PubMed
  • Smith D, Shaffer K, Kirn D, Canellos GP, Mauch PM, Shulman LN. Mediastinal large cell lymphoma: prognostic significance of CT findings at presentation and after treatment. Oncology 1998; 55:284-8. PubMed
  • Gage I, Schnitt SJ, Recht A, Abner A, Come S, Shulman LN, Monson JM, Silver B, Harris JR, Connolly JL. Skin recurrences after breast-conserving therapy for early-stage breast cancer. J Clin Oncol 1998; 16:480-6. PubMed
  • Bunnell CA, Thompson L, Buswell L, Berkowitz R, Muto M, Sheets E, Shulman LN. A Phase I trial of ifosfamide and paclitaxel with granulocyte-colony stimulating factor in the treatment of patients with refractory solid tumors. Cancer 1998; 82:561-6. PubMed
  • Eder JP, Supko JG, Lynch T, Bryant M, Vosburgh E, Shulman LN, Xu G, Kufe DW. Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour continuous intravenous infusion. Clin Cancer Res 1998; 4:317-24. PubMed
  • Sehn LH, Antin JH, Shulman LN, Mauch P, Elias A, Kadin ME, Wheeler C. Primary diffuse large B-cell lymphoma of the mediastinum: outcome following high-dose chemotherapy and autologous hematopoietic cell transplantation. Blood 1998; 91:717-23. PubMed
  • Wong JS, Recht A, Beard CJ, Busse PM, Cady B, Chaffey JT, Come S, Fam S, Kaelin C, Lingos TI, Nixon AJ, Shulman LN, Troyan S, Silver B, Harris JR. Treatment outcome after tangential radiation therapy without axillary dissection in patients with early-stage breast cancer and clinically negative axillary nodes. Int J Radiat Oncol Biol Phys 1997; 39:915-20. PubMed
  • Janicek M, Kaplan W, Neuberg D, Canellos GP, Shulman LN, Shipp MA. Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP chemotherapy. J Clin Oncol 1997; 15:1631-7. PubMed
  • Shaffer K, Smith D, Kirn D, Kaplan W, Canellos G, Mauch P, Shulman LN. Primary mediastinal large-B-cell lymphoma: radiologic findings at presentation. AJR Am J Roentgenol 1996; 167:425-30. PubMed
  • Recht A, Come SE, Henderson IC, Gelman RS, Silver B, Hayes DF, Shulman LN, Harris JR. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med 1996; 334:1356-61. PubMed
  • Shipp MA, Neuberg D, Janicek M, Canellos GP, Shulman LN. High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study. J Clin Oncol 1995; 13:2916-23. PubMed
  • Shulman LN, Buswell L, Goodman H, Muto M, Berkowitz R, Teicher B, Kusumoto T, Hurwitz SJ, Kalish LA, Coleman CN. Phase I pharmacokinetic study of the hypoxic cell sensitizer etanidazole with carboplatin and cyclophosphamide in the treatment of advanced ovarian cancer. Int J Radiat Oncol Biol Phys 1994; 29:545-8. PubMed
  • Ballen KK, Gilliland DG, Kalish LA, Shulman LN. Bone marrow dysplasia in patients with newly diagnosed acute myelogenous leukemia does not correlate with history of myelodysplasia or with remission rate and survival. Cancer 1994; 73:314-21. PubMed
  • Shulman LN, Frisard B, Antin JH, Wheeler C, Pinkus G, Magauran N, Mauch P, Nobles E, Mashal R, Canellos G. Primary Ki-1 anaplastic large-cell lymphoma in adults: clinical characteristics and therapeutic outcome. J Clin Oncol 1993; 11:937-42. PubMed
Hide